merged_eli-lilly-zepbound-price.txt
<other>I will go through each question and find the answer directly from the provided article. I will ensure that the answers are concise and directly address the question. If the information is not available or cannot be logically inferred from the article, I will use "N/A". My primary focus is to adhere strictly to the article's content and the specified output format.</other>
<question_number>1</question_number>
<answer>Offering a safer, FDA-approved option controlled for safety, quality, and effectiveness.</answer>
<question_number>2</question_number>
<answer>By providing a similar telehealth service (online prescriptions and direct delivery) but with an FDA-approved drug, directly competing with their model.</answer>
<question_number>3</question_number>
<answer>Lack of control for safety, quality, and effectiveness due to less oversight compared to traditionally approved medications.</answer>
<question_number>4</question_number>
<answer>To regain customers from the compounded drug market by competing on price, signaling a fight for market share, even if it means some self-cannibalization of its pen sales.</answer>
<question_number>5</question_number>
<answer>Being on the FDA shortage list legally allows compounding pharmacies to make copycat versions; removal from the list would undermine this legal basis and support Lilly's legal challenges.</answer>
<question_number>6</question_number>
<answer>N/A</answer>
<question_number>7</question_number>
<answer>Older patients on Medicare, attracted by lower-cost vials due to lack of insurance coverage for weight-loss drugs, might use them and face unique health risks such as muscle loss, frailty, or fractures.</answer>
<question_number>8</question_number>
<answer>By positioning its vials as a "safer option" and highlighting that compounded drugs are not FDA-approved or controlled for safety, quality, and effectiveness, potentially leading patients to perceive compounded versions as less safe.</answer>
<question_number>9</question_number>
<answer>Being listed by the Food and Drug Administration as "in shortage."</answer>
<question_number>10</question_number>
<answer>Sending a signal to the compounded drug market that Eli Lilly intends to reclaim market share, even if it requires lower pricing for its own products.</answer>